News Releases

Phase 1 trial conducted at Memorial Sloan Kettering Cancer Center , New York , investigated the safety, feasibility and immune activating effects of Olvi-Vec by intrapleural administration. Documented Olvi-Vec infection of tumor cells, which was also associated with reduction in tumor cell density
July 10, 2023
- V2ACT Therapeutics™, LLC is a joint venture between Genelux Corporation and TVAX Biomedical, Inc. - V2ACT Immunotherapy is a proprietary immuno-oncology modality composed of Olvi-Vec (oncolytic viral immunotherapy) and TVAX Immunotherapy ® (vaccine-enhanced adoptive T cell therapy).
June 29, 2023
Displaying 1 - 10 of 25